XmAb-2513

• Description:

  XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP) . XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research[1].

• UNSPSC:

  12352100

• Target:

  TNF Receptor

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer

• References & Citations:

  [1]Lawrence C E, et al. XmAb™ 2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies[J]. 2007.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• Isoform:

  TNFRSF8/CD30